Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
about
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesDipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Retrospective analysis on the efficacy, safety and treatment failure group of sitagliptin for mean 10-month durationPresent and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesDPP-4 inhibitors in clinical practice.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.Sitagliptin: a review.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.DPP-4 inhibitors: focus on safety.Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteersMultiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
P2860
Q26785454-D3EF1F80-3475-4FA1-AB32-A635517D74B4Q35026483-4898074E-1C16-4000-B8AA-9CC8C958B13BQ35110343-F1F5AB5B-F97B-49B3-8209-772AC56272F6Q35909303-DF82D191-6775-47A1-99B0-7A8A4E07CFD2Q37638984-1296E48E-CBEC-46EE-A64F-EA90045FF80DQ37735838-FA588AF1-3B58-4C49-B008-7B6E6B887EA3Q37780914-4379930D-80CB-4D4D-992C-4310D79B0632Q37870930-50450EEB-C030-409E-A4EA-83196F8AFA02Q37886184-AE2D959E-4AE0-4872-BE4C-EEFCB762F627Q38017726-2026024A-5440-4BAF-9CF7-1746620584D2Q38177173-BF0CF992-4F9D-4293-843B-89557AFF6945Q38205588-BA06E4CD-FCD5-4903-B82F-FBEB51D7F17AQ38253580-EF7E4954-7E0F-453E-B949-F4470B717B83Q38285608-00CFBC62-06A0-46B8-87FF-D764333B5DE8Q41958385-6BB505BF-1606-41CF-898C-B554AFAC6262Q43270616-1B7767ED-B954-42DB-AE05-E12866A56847Q53594745-1B63342D-1D51-471B-8813-6F779E4F11C2
P2860
Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@ast
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@en
type
label
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@ast
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@en
prefLabel
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@ast
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@en
P2093
P2860
P1476
Sitagliptin, an dipeptidyl pep ...... glyburide, in healthy subjects
@en
P2093
Arthur J Bergman
David Hreniuk
Gary A Herman
Goutam C Mistry
John A Wagner
Keith M Gottesdiener
Marcella Ruddy
Miguel A Zinny
P2860
P356
10.1111/J.1365-2125.2008.03148.X
P407
P577
2008-05-22T00:00:00Z